Study for Monitoring the Impact of National HPV vaccinaTion program in Japan( Period II : April 2019-December 2026)

Study for Monitoring the Impact of National HPV vaccinaTion program in Japan( Period II: April 2019-December 2026) - Monitoring the Impact of National HPV vaccinaTion program in Japan (MINT study II )

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000038883

Enrollment

4000

Registered

2019-12-16

Start date

2019-07-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical cancer and its precursor lesions

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: All females, aged 16-39 years, who are newly diagnosed with cervical cancer, CIN, or AIS and have not yet been treated

Exclusion criteria

Exclusion criteria: Individuals in either of the groups listed below will be excluded as subjects of the research 1. Female patients younger than 16 or older than 39 years 2. Female who do not have CIN, AIS or cervical cancer

Design outcomes

Primary

Measure	Time frame
The proportion of HPV16/18 positives among subjects of cervical cancer, CIN2/3 and AIS in women aged 16-24, and 25-29 years	—

Secondary

Measure	Time frame
1. The number of women aged 16-24, and 25-29 years who contract cervical cancer,CIN2/3, AIS 2. The proportion of HPV16/18 positives among subjects of CIN1 in women aged 16-24, and 25-29 years 3. The proportion of HPV16/18 positives among subjects of cervical cancer, CIN2/3 and AIS in women aged 16-39 years 4. The distribution of HPV types among subjects of cervical cancer, CIN1/2/3, and AIS in women aged 16-39 years 5. The number of women aged 16-39 years who contract cervical cancer, CIN2/3, and AIS 6. The proportion of HPV16/18 positives among women aged 16-39 years with CIN1 7. The number of deaths from cervical cancer among women aged 16-39 years	—

Measure

Time frame

1. The number of women aged 16-24, and 25-29 years who contract cervical cancer,CIN2/3, AIS 2. The proportion of HPV16/18 positives among subjects of CIN1 in women aged 16-24, and 25-29 years 3. The proportion of HPV16/18 positives among subjects of cervical cancer, CIN2/3 and AIS in women aged 16-39 years 4. The distribution of HPV types among subjects of cervical cancer, CIN1/2/3, and AIS in women aged 16-39 years 5. The number of women aged 16-39 years who contract cervical cancer, CIN2/3, and AIS 6. The proportion of HPV16/18 positives among women aged 16-39 years with CIN1 7. The number of deaths from cervical cancer among women aged 16-39 years

—

Countries

Japan

Contacts

Public ContactYoshitaka Yamaguchi

Showa Medical university Ethics Comittee

m-rinri@ofc.showa-u.ac.jp03-3784-8129

Outcome results